India, June 17 -- Biotechnology company Capricor Therapeutics, Inc. (CAPR) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Deramiocel, the company's lead cell therapy candidate, for the potential treatment of Becker Muscular Dystrophy (BMD).
This designation strengthens Capricor's strategic position as it advances a fully integrated platform targeting the cardiac and skeletal complications of muscular dystrophy and expands the commercial potential of its lead asset.
The company said Deramiocel has demonstrated potential to treat the serious cardiac and skeletal muscle complications of Duchenne Muscular Dystrophy, and based on the overlap in disease pathology, may also offer benefit...